Cyclophosphamide is an alkylating agent used to treat haematologic malignant diseases and multisystem diseases with progressive glomerulonephritis. It is rarely prescribed during pregnancy. We report a case of Henoch-Schönlein purpura discovered at the end of the first trimester of pregnancy. Despite steroid therapy, glomerulonephritis worsened and 100 mg/day cyclophosphamide per os was administered from 28th week till delivery. The infant, prematurely born, was normal and did not have any haematological disorder. Congenital malformations are often reported (5 out of 19 newborns exposed in utero to cyclophosphamide), but in all those cases, there was another potentially teratogenic agent: either radiotherapy or another antineoplastic drug. Therefore, if mother's life is in jeopardy, cyclophosphamide therapy should be given and not postponed.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Boric Acid Protects the Uterus and Fallopian Tubes from Cyclophosphamide-Induced Toxicity in a Rat Model.
Pharmaceuticals (Basel)
December 2024
School of Health Sciences, Cappadocia University, Nevsehir 50400, Turkey.
: Cyclophosphamide (CP) is widely used for treating various cancers and autoimmune diseases, but it causes damage to reproductive organs due to oxidative stress (OS) and inflammation. Boric acid (BA) has antioxidant properties that may help reduce OS, which is critical for preserving uterine functionality, particularly for cancer patients considering pregnancy after cryopreservation. This study aimed to determine whether BA could diminish CP-induced toxicity in the uterus and fallopian tubes (FT) using CP-induced toxicity in a rat model.
View Article and Find Full Text PDF[Clinical Analysis of 25 Cases of Acquired Hemophilia A in a Single Center].
Zhongguo Shi Yan Xue Ye Xue Za Zhi
December 2024
Department of Hematology, The Second Hospital of Hebei Medical University, Hebei Key Laboratory of Hematology, Shijiazhuang 050000, Hebei Province, China.
Objective: To explore the diagnosis and treatment of acquired hemophilia A (AHA) based on the analysis of clinical data.
Methods: A retrospective analysis was conducted on the clinical manifestations, laboratory characteristics, treatment, and outcomes of 25 patients diagnosed with AHA who were admitted to the Second Hospital of Hebei Medical University.
Results: Among all patients, 11 cases had secondary factors, including 5 cases of autoimmune diseases, 3 cases of pregnancy-related disease, 1 case of pemphigoid, 1 case of Graves' disease, and 1 case of monoclonal gammaglobulinemia of unknown significance (MGUS).
Compound-dependent fetal toxicity after in utero exposure to chemotherapy in a pregnant mouse model.
Environ Toxicol Pharmacol
December 2024
Department of Oncology, KU Leuven, Leuven, Belgium; Department of Obstetrics and Gynecology, UZ Leuven, Leuven, Belgium; Gynecologic Oncology, Netherlands Cancer Institute, Anthony Van Leeuwenhoek, Amsterdam, the Netherlands. Electronic address:
Although chemotherapy is integrated in the treatment of second-trimester pregnant cancer patients, its potential cyto- and genotoxicity to fetal tissue remains unknown. To investigate any causal relation between in utero chemotherapy exposure and fetal toxicity, late-gestation pregnant BL6 mice were exposed to vehicle, or one of six chemotherapeutic compounds, used to treat pregnant cases: cyclophosphamide, carboplatin, cisplatin (alkylating agents), epirubicin, doxorubicin (anthracyclines) or paclitaxel (taxane). fetuses were euthanized at gestational day 18.
View Article and Find Full Text PDFTREATMENT OUTCOMES OF GESTATIONAL TROPHOBLASTIC DISEASE, EXPERIENCE FROM SAUDI ARABIA.
J Ayub Med Coll Abbottabad
November 2024
Department of Medical Oncology, Prince Sultan Military Medical City, Riyadh-Saudi Arabia.
Background: This research aims to assess the treatment outcomes and chemotherapy duration required for the normalization of Human chorionic gonadotropin (HCG) levels in patients diagnosed with Gestational Trophoblastic Neoplasia (GTN), encompassing both benign and malignant forms of the condition.
Methods: This retrospective study included GTD patients treated with chemotherapy in a single oncology clinic from January 2016 to May 2022. Clinical data were gathered from electronic records of the patients.
Development and validation of an UPLC-ESI-MS/MS method for simultaneous quantification of antineoplastic agents and their metabolites in human plasma after unintentional exposure.
Arch Toxicol
January 2025
Centre for Environment and Health, Department of Public Health and Primary Care, KU Leuven, Herestraat 49, 3000, Leuven, Belgium.
Article Synopsis
- A variety of commonly used cancer drugs like cyclophosphamide, daunorubicin, epirubicin, doxorubicin, and paclitaxel lack simultaneous measurement methods for their levels and metabolites in human plasma.
- The research developed a sensitive method using solid phase extraction, UPLC, and tandem mass spectrometry, validating it based on various criteria such as sensitivity and precision.
- The method was successfully tested on plasma samples from pregnant cancer patients, detecting cyclophosphamide concentrations, indicating its practical application for monitoring drug exposure.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!